[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 18, Issue 3 (7-2020) ::
Int J Radiat Res 2020, 18(3): 383-388 Back to browse issues page
Clinical outcome of stereotactic body radiotherapy for localized prostate cancer: long-term results
H.J. Kim , J.S. Lee, W.C. Kim
Department of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, Korea , cancerovercome@gmail.com
Abstract:   (2040 Views)
Background: Stereotactic body radiotherapy (SBRT) is an emerging treatment option which allows for extreme hypofractionation using modern technologies, because the low α/β-ratio favors the use of high dose per fraction in prostate cancer. There is a need for more data about SBRT. We provide a long-term update of SBRT clinical outcome using CyberKnife for the treatment of localized prostate cancer. Materials and Methods: This study was based on a retrospective analysis of 43 patients treated with SBRT using CyberKnife for localized prostate cancer (23.3% in low risk, 67.4% in intermediate risk and 9.3% in high risk). The target volume included the prostate with or without the seminal vesicles depending on the risk stratification and uncertainty margins that are kept at 3-5 mm. Total dose of 36.25 Gy in 5 fractions of 7.25 Gy were administered. Results: 43 patients with a median 73.6 months (range, 14 to 119 months) follow-up were analyzed. There was three biochemical failure (BCF). Eight-year BCF free survival and overall survival were 92.0% and 73.1%, respectively. Median PSA decline rates were -0.301, -0.191 and -0.115 ng/mL/month, respectively, for durations of 1, 2 and 3 years after radiotherapy and has remained plateau. Median PSA nadir was 0.27 ng/mL at median 38 months and PSA bounce (median 0.33 ng/mL) occurred in 32.6% (n = 14) of patients at median 19 months after SBRT. There was no grade 3 acute and late toxicity. Conclusion: Our long-term experience with SBRT using CyberKnife for localized prostate cancer demonstrates favorable efficacy and toxicity.
Keywords: CyberKnife, prostate cancer, stereotactic body radiotherapy, prostate-specific antigen, radiotherapy, hypofractionation.
Full-Text [PDF 1615 kb]   (534 Downloads)    
Type of Study: Original Research | Subject: Medical Physics
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kim H, Lee J, Kim W. Clinical outcome of stereotactic body radiotherapy for localized prostate cancer: long-term results. Int J Radiat Res. 2020; 18 (3) :383-388
URL: http://ijrr.com/article-1-2968-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 18, Issue 3 (7-2020) Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.04 seconds with 32 queries by YEKTAWEB 4341